Literature DB >> 9230728

Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency.

E Eden1, D Mitchell, B Mehlman, H Khouli, M Nejat, M H Grieco, G M Turino.   

Abstract

Bronchial asthma is characterized by episodic airway obstruction and associated with wheezing, a bronchodilator response, an elevation in total serum IgE, and atopy. To determine whether asthma is more common in subjects with severe alpha 1-antitrypsin deficiency (alpha 1-ATD) and airway obstruction, we compared 38 patients who had this condition (Group 1) with 22 control patients with chronic obstructive pulmonary disease (COPD) (Group 2) and with five subjects with alpha 1-ATD and normal spirometry (Group 3). Subjects were evaluated with a symptom questionnaire, pulmonary function testing, intradermal allergen testing, and serum IgE measurement. Self-reported wheezing was a common symptom in all patient groups, but attacks of wheezing with dyspnea were significantly more common in Group 1. Of those patients with airway obstruction, more than 50% showed a bronchodilator response whether suffering from alpha 1-ATD or not. Atopy was more common in Group 1 than in Group 2 (48% versus 27%). Mean serum IgE for all groups was similar but significantly greater in patients with atopy. We estimated the prevalence of asthma in the study groups on the basis of the criteria of attacks of wheezing, reversible airway obstruction, atopy, and that increased IgE. The proportion of patients with asthma in Group 1 was significantly greater than that in Group 2 (22% versus 5%, p < 0.05). Our study shows that with control for the degree of airway obstruction, asthma, as defined, is more common in patients with alpha 1-ATD than in those without it. We suggest that a lack of alpha 1-AT in airways increases the propensity to develop asthma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230728     DOI: 10.1164/ajrccm.156.1.9508014

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  25 in total

Review 1.  Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease.

Authors:  Sarah K Brode; Simon C Ling; Kenneth R Chapman
Journal:  CMAJ       Date:  2012-07-03       Impact factor: 8.262

2.  Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.

Authors:  Dawn L Demeo; Robert A Sandhaus; Alan F Barker; Mark L Brantly; Edward Eden; N Gerard McElvaney; Stephen Rennard; Esteban Burchard; James M Stocks; James K Stoller; Charlie Strange; Gerard M Turino; Edward J Campbell; Edwin K Silverman
Journal:  Thorax       Date:  2007-03-27       Impact factor: 9.139

3.  Quantitative airway assessment on computed tomography in patients with alpha1-antitrypsin deficiency.

Authors:  Tsuneo Yamashiro; Shin Matsuoka; Raúl San José Estépar; Alejandro Diaz; John D Newell; Robert A Sandhaus; Patricia J Mergo; Mark L Brantly; Sadayuki Murayama; John J Reilly; Hiroto Hatabu; Edwin K Silverman; George R Washko
Journal:  COPD       Date:  2009-12       Impact factor: 2.409

4.  Respiratory symptoms and lung function in young adults with severe alpha(1)-antitrypsin deficiency (PiZZ).

Authors:  E Piitulainen; T Sveger
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 5.  The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations.

Authors:  Samuel Louie; Amir A Zeki; Michael Schivo; Andrew L Chan; Ken Y Yoneda; Mark Avdalovic; Brian M Morrissey; Timothy E Albertson
Journal:  Expert Rev Clin Pharmacol       Date:  2013-03       Impact factor: 5.045

Review 6.  Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology.

Authors:  D A Lomas; H Parfrey
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

7.  Association between the N-acetylation genetic polymorphism and bronchial asthma.

Authors:  Muradiye Nacak; A Sükrü Aynacioglu; Ayten Filiz; Ingolf Cascorbi; M Emin Erdal; Necat Yilmaz; Erhan Ekinci; Ivar Roots
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

Review 8.  Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy.

Authors:  Joanna Wozniak; Tomasz Wandtke; Piotr Kopinski; Joanna Chorostowska-Wynimko
Journal:  Hum Gene Ther       Date:  2015-09-29       Impact factor: 5.695

9.  Effect of recombinant α1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes.

Authors:  Siyoung Lee; Youngmin Lee; Kwangwon Hong; Jaewoo Hong; Suyoung Bae; Jida Choi; Hyunjhung Jhun; Areum Kwak; Eunsom Kim; Seunghyun Jo; Charles A Dinarello; Soohyun Kim
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

10.  IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency.

Authors:  Dawn L Demeo; Edward J Campbell; Alan F Barker; Mark L Brantly; Edward Eden; N Gerard McElvaney; Stephen I Rennard; Robert A Sandhaus; James M Stocks; James K Stoller; Charlie Strange; Gerard Turino; Edwin K Silverman
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.